Ongoing research continues to refine our understanding of these medications
Eli Lilly published the results of its ATTAIN-1b trial for obesity in September 2025 7 , which compared orforglipron to placebo in more than 3,100 adults without diabetes, with a BMI of 30+ or 27-30 with an obesity-related complication including hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea and a history of at least one patient-reported unsuccessful dietary effort to lose body weight, who have tried unsuccessfully to lose weight with diet alone
GLP-1 is also secreted by a small population of neurons in the hindbrain (Richard et al., 2015)
Treatment The Glutathione injection is administered directly into the bloodstream, typically through an intramuscular or intravenous injection
One of them, glucagon-like peptide (GLP)-1, has glucose-lowering properties [4, 5] and has been the basis of two novel classes of glucose-lowering agents, incretin mimetics (i.e